William Blair Has Pessimistic Outlook of BDX Q1 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at William Blair dropped their Q1 2025 EPS estimates for Becton, Dickinson and Company in a research report issued on Friday, November 8th. William Blair analyst A. Brackmann now forecasts that the medical instruments supplier will post earnings per share of $3.13 for the quarter, down from their previous estimate of $3.17. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.37 per share. William Blair also issued estimates for Becton, Dickinson and Company’s Q2 2025 earnings at $3.50 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $4.01 EPS and FY2025 earnings at $14.37 EPS.

BDX has been the subject of several other reports. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $231.26 on Monday. The company has a quick ratio of 1.36, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average price is $236.88 and its two-hundred day moving average price is $235.13. The company has a market cap of $66.84 billion, a PE ratio of 38.93, a price-to-earnings-growth ratio of 1.73 and a beta of 0.43. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.42 EPS.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. Charles Schwab Investment Management Inc. increased its stake in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the period. PineStone Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after purchasing an additional 788,735 shares during the period. M&G Plc acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $173,692,000. First Eagle Investment Management LLC lifted its position in Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after buying an additional 460,440 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.